Market Overview - U.S. stocks experienced a decline, with the Nasdaq Composite falling over 100 points on Monday. The Dow decreased by 0.43% to 48,500.27, the NASDAQ dropped 0.52% to 23,470.77, and the S&P 500 fell 0.34% to 6,906.49 [1] Sector Performance - Energy shares increased by 1.1% on Monday, while materials stocks fell by 1.3% in trading on Friday [1] Commodity Market - In commodity news, oil prices rose by 2.5% to $58.14, while gold prices decreased by 4.6% to $4,360.50. Silver fell by 8.1% to $70.925, and copper dropped by 4.3% to $5.5900 [5] European Market - European shares showed mixed results, with the eurozone's STOXX 600 gaining 0.1%, while Spain's IBEX 35 Index fell by 0.1%. London's FTSE 100 rose by 0.1%, Germany's DAX 40 decreased by 0.1%, and France's CAC 40 increased by 0.1% [6] Asian Market - Asian markets closed mostly lower, with Japan's Nikkei 225 down 0.44%, Hong Kong's Hang Seng Index down 0.71%, China's Shanghai Composite up 0.04%, and India's BSE Sensex down 0.41% [7] Company News - Eightco Holdings Inc. shares surged by 28% to $2.12 after announcing a share buyback program for up to $125 million [9] - Brand Engagement Network, Inc. shares increased by 64% to $1.97 following a finalized Vendor Services Project Agreement with a global advertising agency [9] - Society Pass Incorporated shares rose by 65% to $3.00 after launching TMG Social [9] - Mereo BioPharma Group plc shares plummeted by 90% to $0.23 after its Phase 3 studies for setrusumab did not meet primary endpoints [9] - Ultragenyx Pharmaceutical Inc. shares fell by 42% to $19.84 due to similar study results as Mereo [9] - Hycroft Mining Holding Corporation shares decreased by 14% to $21.61 as precious metal stocks retreated [9] Real Estate Market - U.S. pending home sales increased by 3.3% month-over-month in November, following a revised 2.4% gain in October, exceeding market expectations of a 1% gain [2][10]

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 100 points, down 0.25% to 48,591.37, NASDAQ down 0.55% to 23,464.42, and S&P 500 down 0.34% to 6,906.41 [1] Sector Performance - Energy shares rose by 0.6% while materials stocks fell by 1.1% on the same day [1] Real Estate Market - U.S. pending home sales increased by 3.3% month-over-month in November, following a revised 2.4% gain in October, exceeding market estimates of a 1% gain [2][10] Commodity Market - Oil prices increased by 2.5% to $58.13, while gold prices decreased by 4.2% to $4,360.50. Silver fell by 6.8% to $71.945, and copper dropped by 4.6% to $5.5725 [5] European Market - European shares showed mixed results, with the eurozone's STOXX 600 gaining 0.1%, while Germany's DAX 40 fell by 0.1% [6] Asian Market - Asian markets closed mostly lower, with Japan's Nikkei 225 down 0.44% and Hong Kong's Hang Seng Index down 0.71% [7] Company Performance - CCSC Technology International Holdings Limited shares surged 93% to $0.2516. Brand Engagement Network, Inc. shares rose 77% to $2.1200 after a project agreement. Society Pass Incorporated shares increased by 58% to $2.88 following a new launch [9] - Mereo BioPharma Group plc shares dropped 89% to $0.2436 after failing to meet primary endpoints in clinical studies. Ultragenyx Pharmaceutical Inc. shares fell 41% to $20.10 due to the same study results [9]

Core Viewpoint - Mereo BioPharma Group's shares plummeted significantly after the announcement that its Phase 3 studies for setrusumab in Osteogenesis Imperfecta did not meet primary endpoints, leading to a broader impact on related stocks in pre-market trading [1][3]. Company Performance - Mereo BioPharma Group shares fell 87.5% to $0.29 in pre-market trading following the disappointing study results [2]. - Ultragenyx Pharmaceutical Inc shares dropped 43.7% to $19.26 as a result of the same study outcomes [3]. - A SPAC III Acquisition Corp shares decreased by 11.7% to $21.21 after a significant rise of 79% on the previous Friday [3]. - Sellas Life Sciences Group Inc shares fell 7.6% to $2.65 after providing an update on its Phase 3 REGAL trial [3]. - Alvotech SA shares dipped 6.8% to $4.90 in pre-market trading [3]. - Sigma Lithium Corp shares tumbled 5.5% to $13.70 after a prior gain of 7% [3].

Core Viewpoint - HC Wainwright has initiated coverage on Ultragenyx Pharmaceuticals, Inc. with a Buy rating and a price target of $80, highlighting it as an attractive investment opportunity despite a 35% year-to-date decline in its stock price compared to a 2.7% decline in the XBI index [1][2]. Group 1: Company Performance and Trials - Ultragenyx's stock has faced pressure primarily due to investor disappointment regarding the interim results from the pivotal Orbit trial of UX143 (setrusumab) for osteogenesis imperfecta [2]. - The Phase 3 portion of the Orbit study is progressing towards a final analysis by the end of the year, with the second interim analysis not meeting the minimal p-value threshold to conclude the study early [3]. - The analyst believes the Orbit trial has not failed, and positive final results are anticipated, which should support a U.S. regulatory filing for setrusumab next year [4]. Group 2: Commercial Portfolio and Future Prospects - Ultragenyx's current commercial portfolio is estimated to support a fair value of approximately $35-$40 per share, excluding the potential contributions from its pipeline [4]. - The flagship Crysvita franchise is projected to achieve peak annual sales exceeding $3 billion [5]. - The company is expected to resubmit its Biologics License Application (BLA) for UX111 (ABO-102) later this year, with potential approval anticipated by mid-2026, addressing a high unmet need in the Sanfilippo syndrome market [6][7].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Ultragenyx Pharmaceutical Inc. and its officers or directors [1] Group 1: Company Developments - On July 9, 2025, Ultragenyx and Mereo BioPharma Group plc announced progress in the Phase 3 Orbit study for UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta, with a final analysis expected around the end of the year [3] - Following the announcement, Ultragenyx's stock price dropped by $10.41 per share, or 25.11%, closing at $31.04 per share on July 10, 2025 [3] Group 2: Legal Context - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Group 1 - Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - On July 9, 2025, Ultragenyx and Mereo BioPharma Group announced the progress of the Phase 3 Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta, with a final analysis expected by the end of the year [3] - Following the announcement, Ultragenyx's stock price dropped by $10.41, or 25.11%, closing at $31.04 per share on July 10, 2025 [3] Group 2 - The Pomerantz Firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having pioneered the field of securities class actions over 80 years ago [4] - The firm has a history of recovering multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

Core Insights - Ultragenyx Pharmaceutical (RARE) and Mereo BioPharma (MREO) have provided an update on the mid-to-late-stage Orbit study for UX143 (setrusumab) aimed at treating osteogenesis imperfecta (OI) in pediatric and young adult patients, with final analysis expected by the end of 2025 [1][5] - The shares of both companies experienced a significant decline in premarket trading following the announcement of the delay in new data from the Orbit study [2][5] - UX143 is a fully human monoclonal antibody that inhibits sclerostin, and interim safety data has shown an acceptable safety profile, allowing the study to proceed as planned [2][5] Study Details - The Orbit study is assessing the impact of UX143 on fracture rates in patients aged 5 to 25 with OI, with a pivotal phase III portion enrolling 159 additional patients [7] - The primary efficacy endpoint of the Orbit study is to reduce the annualized clinical fracture rate, with participants moving into an open-label extension period after the primary analysis [7] - The Cosmic study targets a younger population aged two to under seven years, comparing UX143 to intravenous bisphosphonates for fracture reduction, with 69 patients enrolled [8] Partnership and Market Context - Ultragenyx Pharmaceuticals and Mereo BioPharma entered a licensing agreement in 2020 for the joint development of UX143, with RARE holding exclusive rights in several regions [9] - The partnership was expanded in 2024 through a manufacturing and supply agreement, with RARE responsible for supplying setrusumab to MREO [9] - OI affects approximately 60,000 individuals in commercially accessible geographies, and there are currently no approved treatments available [11]

Core Viewpoint - Ultragenyx Pharmaceutical Inc. and Mereo BioPharma Group plc stocks are experiencing significant declines following the update on the Phase 3 Orbit study for UX143 (setrusumab) in patients with osteogenesis imperfecta (OI) [1][2]. Group 1: Study Progress and Analysis - The Phase 3 portion of the Orbit study is progressing towards a final analysis expected by the end of the year, in line with the original plan [2]. - The second interim analysis did not meet the minimal p-value threshold of p<0.01, which would have allowed the study to conclude early [3]. - The Data Monitoring Committee confirmed that UX143 has an acceptable safety profile, recommending the continuation of the study [3][4]. Group 2: Future Expectations - The final analyses for the Orbit and Cosmic studies will occur after patients have been on therapy for at least 18 months, with thresholds set at p<0.04 for Orbit and p<0.05 for Cosmic [5]. - Analysts express optimism regarding the final analysis, anticipating a positive outcome due to longer follow-up duration and a lower statistical significance threshold [6]. Group 3: Market Reaction - Following the update, RARE stock has dropped by 26.2% to $30.60, while MREO stock has decreased by 34.7% to $1.919 [7].

Group 1: Methode Electronics - Methode Electronics reported a fourth-quarter adjusted EPS loss of 77 cents per share, missing market estimates of earnings of 4 cents per share [1] - The company's sales were $257.10 million, exceeding estimates of $232.87 million [1] - Shares of Methode Electronics fell sharply in pre-market trading following the earnings report [1] Group 2: Other Stocks - Mereo BioPharma Group plc shares tumbled 36.6% to $1.87 in pre-market trading [4] - Ultragenyx Pharmaceutical Inc. shares dipped 21.3% to $32.50 in pre-market trading [4] - Wolfspeed, Inc. shares fell 11% to $1.79 in pre-market trading after a 20% drop on Wednesday [4] - Scage Future shares fell 10.5% to $5.89 in pre-market trading after a significant gain of over 56% on Wednesday [4] - Altimmune, Inc. shares dipped 8.4% to $4.34 in pre-market trading following the initiation of a Phase 2 trial [4] - Bitmine Immersion Technologies, Inc. shares fell 7.7% to $61.60 in pre-market trading after a 40% drop on Wednesday due to a mixed shelf filing [4] - Hotel101 Global Holdings Corp. shares dipped 5.3% to $3.42 in after-hours trading [4] - Metsera, Inc. shares fell 4.3% to $33.80 in pre-market trading after a 17% gain on Wednesday [4]

Core Insights - The Phase 3 Orbit study for UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is on track for final analysis by the end of the year [1][3] - The Data Monitoring Committee has confirmed an acceptable safety profile for UX143, allowing the study to proceed [2] - Ultragenyx and Mereo BioPharma are collaborating on the development of setrusumab, targeting OI sub-types I, III, and IV [5][12] Study Details - The Phase 3 Orbit study has enrolled 159 patients across 45 sites in 11 countries, with a primary efficacy endpoint focused on annualized clinical fracture rate [7] - The Cosmic study, which is also in Phase 3, has enrolled 69 patients aged 2 to <7 years, comparing setrusumab to intravenous bisphosphonates [8] - Both studies will conduct final analyses after patients have been on therapy for at least 18 months, with specific statistical thresholds set for each study [4] Background on Osteogenesis Imperfecta - OI is a genetic disorder affecting bone metabolism, primarily caused by mutations in the COL1A1 or COL1A2 genes, leading to increased bone brittleness and a high rate of fractures [9] - Approximately 60,000 individuals are affected by OI in commercially accessible regions, with no globally approved treatments available [9] Mechanism of Setrusumab - Setrusumab is a fully human monoclonal antibody that inhibits sclerostin, which negatively regulates bone formation, potentially increasing bone mass and strength [10] - Previous studies have shown that anti-sclerostin antibodies can significantly improve bone formation and density in OI models [11] Company Profiles - Ultragenyx is focused on developing therapies for rare genetic diseases, with a portfolio aimed at addressing high unmet medical needs [13] - Mereo BioPharma is also dedicated to innovative therapeutics for rare diseases, with setrusumab as one of its key candidates [15]